TORONTO, Nov. 24, 2021 (GLOBE NEWSWIRE) -- PharmaTher Holdings Ltd. (the “Company” or “PharmaTher”) (OTCQB: PHRRF) (CSE: PHRM), a clinical-stage psychedelics biotech company, is pleased to announce ...
Please provide your email address to receive an email when new articles are posted on . The FDA granted orphan drug designation to PharmaTher for its status epilepticus ketamine treatment, according ...
Drexel University College of Medicine researchers are conducting an emergency medicine study to find out the most effective drug for treating established status epilepticus -- a life-threatening ...
PharmaTher, a Toronto-based biotechnology company focused on discovering and developing drugs using Ketamine, received an Orphan Drug Designation (ODD) for a ketamine-based medicine to treat a rare ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results